First Choice Neurology

BAN2401 Study to Assess New Alzheimer’s Treatment

If you or a loved one are experiencing signs of early Alzheimer’s disease, there may soon be treatment and hope on the horizon. First Choice Neurology is participating in an FDA-approved Phase III clinical trial to determine the benefit of an experimental product, BAN2401.   What is BAN2401 for Alzheimer’s? BAN2401 is a new class…

Moving Day Miami Helps Support Parkinson’s

Moving Day Miami is an annual fundraiser for The Parkinson’s Foundation. Moving Day Miami will be held this Saturday, November 9 at Maurice A. Ferré Park located at 1075 Biscayne Blvd, Miami, FL 33132. Moving Day Miami is more than just a walk. It highlights movement and exercise as a symbol of hope and progress…

HAPPIN Study Seeks Patients with Idiopathic Neuropathy

First Choice Neurology is launching the HAPPIN Study (Hereditary Amyloid Polyneuropathy Prevalence in Idiopathic Neuropathy). It is the nation’s first research study of the prevalence of hereditary amyloid neuropathy. Doctors at First Choice Neurology will be evaluating a large group of patients with idiopathic neuropathy to determine if they possess a hereditary marker for amyloid…

Biogen Seeks FDA Approval for New Alzheimer’s Drug

Biogen is planning to file for U.S. regulatory approval for its Alzheimer’s treatment aducanumab after data from more patients in two discontinued studies showed that the drug improved cognition at high doses. Patients who received aducanumab experienced significant benefits on measures of cognition and function such as memory, orientation, and language, Biogen said. In March,…

Treating Hereditary ATTR Amyloidosis with Polyneuropathy

Reposted from Neurology Advisor – written by Jeffrey A. Allen, M.D. Hereditary transthyretin-related amyloidosis (hATTR) with polyneuropathy is a rare, progressive, fatal disease that has been challenging for neurologists to diagnose and manage, until now. This disease, which often presents first with polyneuropathy, is caused by misfolding of the transthyretin (TTR) proteins produced in the liver due…

Early Intervention Provides Hope to Children Diagnosed with Epilepsy

Article was written by South Florida Hospital News and Healthcare Report Adam and Monica Adache knew something wasn’t right when their daughter, Maya, had a seizure at only six months old. When those seizures continued to happen, they became extremely concerned. During one episode, she also had a high fever and her pediatrician recommended she…

Seizures and Epilepsy

By Bruno V. Gallo, MD Epilepsy has been common throughout history. Somewhere around 3.4 million Americans suffer from epilepsy. In years past the general population held on to a belief that convulsions and seizures were a condition of the young. This is no longer a valid statement. The incidence of epilepsy (ie, the number of…

Dr. Brian Costell Talks About Why He Joined First Choice Neurology

Dr. Brian Costell joined First Choice Neurology because it was a single-specialty neurology group and not a multi-specialty group. Dr. Costell said, “Being a part of a single-specialty neurology group, we gain all of the knowledge of working together and basically doing the same job for the same goal. Our other option was to join…

Medical Marijuana and Medical Cannabis

What is Medical Marijuana? Medical marijuana, or medical cannabis, is plant-based from the cannabis species with two active compounds THC and CBD. The medicine contains more than 100 different chemicals called cannabinoids. Each one has a different effect on the body. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the main chemicals used in medicine. Medical marijuana…

Translate »